CytomX Therapeutics has updated its pipeline priorities for 2025, highlighting its lead program, CX-2051, a first-in-class PROBODY ADC targeting EpCAM for advanced metastatic colorectal cancer, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback